Rituximab Linked to 10-fold Higher IBD Risk in MS

03 Nov 2026 0 comments

The anti-CD20 medication rituximab was linked to a nearly 10-fold higher risk for IBD in patients with MS than with other therapies, although the absolute risk remains low.
Medscape Medical News

Source: Medscape Neurology Published 03 Nov 2026 Imported 03 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment